NCT01273272

Brief Summary

The purpose of this study is to determine whether a comprehensive cognitive-behavioral therapy-based, multi-component treatment programme is effective in the treatment of neuropsychiatric symptoms of patients with mild Alzheimer's dementia.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for phase_2 alzheimer-disease

Timeline
Completed

Started Feb 2011

Longer than P75 for phase_2 alzheimer-disease

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 3, 2011

Completed
7 days until next milestone

First Posted

Study publicly available on registry

January 10, 2011

Completed
22 days until next milestone

Study Start

First participant enrolled

February 1, 2011

Completed
6.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2017

Completed
Last Updated

November 6, 2017

Status Verified

November 1, 2017

Enrollment Period

6.6 years

First QC Date

January 3, 2011

Last Update Submit

November 1, 2017

Conditions

Keywords

Cognitive Behavior TherapyEarly dementia, Alzheimer type

Outcome Measures

Primary Outcomes (1)

  • Change from baseline in Geriatric Depression Scale (GDS)

    Pre-treatment, posttreatment (expected average of 9 months after protreatment), 6- and 12-months follow-up

Secondary Outcomes (10)

  • Change from baseline in Neuropsychiatric Inventory (NPI)

    Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up

  • Change from baseline in Bayer-Activities of Daily Living (B-ADL)

    Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up

  • Change from baseline in Stress Coping Inventory (SCI)

    Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up

  • Change from baseline in Apathy Evaluation Scale (AES)

    Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up

  • Caregiver: Change from baseline in Center for Epidemiologic Studies Depression Scale (CES-D)

    Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up

  • +5 more secondary outcomes

Study Arms (2)

Cognitive Behavioral Therapy (CBT)

EXPERIMENTAL

Comprehensive, CBT-based, multi-component treatment. Comprehensive CBT intervention in addition to standard treatment

Behavioral: Comprehensive, CBT-based, multi-component treatment

Treatment as usual (TAU)

ACTIVE COMPARATOR

Standard Treatment (medical and psychosocial)

Behavioral: Treatment as usual

Interventions

It includes eight modules: diagnosis and goal setting; psychoeducation; engagement in pleasant activities; cognitive restructuring; live review; training caregiver in behavior man-agement techniques; interventions for the caregiver; and couples counselling. It consists of 20 weekly sessions (plus appr. 5 single session with caregiver).

Also known as: Psychosocial intervention
Cognitive Behavioral Therapy (CBT)

Each patient/caregiver must receive at least three out of six interventions: (1) psychoeducation on dementia and treatment of dementia (oral and written); (2) appropriate medical treatment; (3) social counseling by specialized staff; (4) memory training in group setting; (5) self-help group for the patient; (6) self-help group for the caregiver.

Also known as: Standard treatment
Treatment as usual (TAU)

Eligibility Criteria

Age50 Years - 95 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients have to meet NINCDS-ADRDA criteria for probable or possible AD (McKhann et al., 1984). Mixed Alzheimer and Vascular dementia cases will also be included.
  • Only AD cases with a mild dementia severity will be included, determined by the Clinical Dementia Rating (CDR) scale (i.e. scores of 0.5 or 1, Morris, 1993) and by the Mini Mental State Examination (MMSE) (i.e. scores of 20 or more, Folstein, Folstein, \& McHugh, 1975).
  • The patient must suffer under any non-cognitive symptom that motivates him to accept psy-chotherapeutic help.
  • A caregiver must be available to take part in most of the therapy sessions.

You may not qualify if:

  • concomitant alcohol or drug addiction and a history of a malignant disease, severe organ failure, metabolic or hematologic disorders, neurosurgery or neurological condition such as Parkinson's disease, epilepsy, postencephalitic and postconcussional syndrome

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Psychiatric University Hospital, Clinic for Geriatric Medicine

Zurich, 8032, Switzerland

Location

Related Publications (4)

  • Forstmeier S, Maercker A. Problems of aging. Psychotherapy in older age [German]. Göttingen, Germany: Hogrefe. 2008.

    BACKGROUND
  • Forstmeier S, Maercker A. Psychotherapie im Alter. Psychotherapeutenjournal 4: 340-352, 2007

    BACKGROUND
  • Forstmeier S, Maercker A, Savaskan E, Roth T. Cognitive behavioural treatment for mild Alzheimer's patients and their caregivers (CBTAC): study protocol for a randomized controlled trial. Trials. 2015 Nov 17;16:526. doi: 10.1186/s13063-015-1043-0.

    PMID: 26576633BACKGROUND
  • Forstmeier S, Maercker A, Bohli L, Savaskan E, Roth T. Cognitive behavioural treatment for mild Alzheimer's patients and their caregivers (CBTAC): results of a randomised controlled trial. Aging Ment Health. 2025 Feb;29(2):359-368. doi: 10.1080/13607863.2024.2393748. Epub 2024 Aug 20.

MeSH Terms

Conditions

Alzheimer Disease

Interventions

Psychosocial InterventionTherapeutics

Condition Hierarchy (Ancestors)

DementiaBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental Disorders

Intervention Hierarchy (Ancestors)

PsychotherapyBehavioral Disciplines and Activities

Study Officials

  • Simon Forstmeier, Ph.D.

    University of Zurich

    PRINCIPAL INVESTIGATOR
  • Andreas Maercker, M.D.,Ph.D.

    University of Zurich

    STUDY CHAIR
  • Egemen Savaskan, M.D.

    Psychiatric University Hospital, Zurich

    STUDY CHAIR
  • Tanja Roth, Ph.D.

    Psychiatric University Hospital, Zurich

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Ph.D.

Study Record Dates

First Submitted

January 3, 2011

First Posted

January 10, 2011

Study Start

February 1, 2011

Primary Completion

September 1, 2017

Study Completion

September 1, 2017

Last Updated

November 6, 2017

Record last verified: 2017-11

Locations